Madrigal Pharmaceuticals (MDGL) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Madrigal Pharmaceuticals (MDGL) over the last 10 years, with Q3 2025 value amounting to -$5.08.
- Madrigal Pharmaceuticals' EPS (Weighted Average and Diluted) fell 325.2% to -$5.08 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.89, marking a year-over-year increase of 4860.45%. This contributed to the annual value of -$21.9 for FY2024, which is 955.81% down from last year.
- Per Madrigal Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at -$5.08 for Q3 2025, which was down 325.2% from -$1.9 recorded in Q2 2025.
- In the past 5 years, Madrigal Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of -$1.9 in Q2 2025 and a low of -$7.38 during Q1 2024
- For the 5-year period, Madrigal Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around -$4.46, with its median value being -$4.23 (2023).
- In the last 5 years, Madrigal Pharmaceuticals' EPS (Weighted Average and Diluted) tumbled by 7446.81% in 2024 and then skyrocketed by 7323.94% in 2025.
- Over the past 5 years, Madrigal Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$3.9 in 2021, then fell by 28.41% to -$5.01 in 2022, then fell by 19.77% to -$6.0 in 2023, then surged by 53.48% to -$2.79 in 2024, then plummeted by 81.88% to -$5.08 in 2025.
- Its EPS (Weighted Average and Diluted) was -$5.08 in Q3 2025, compared to -$1.9 in Q2 2025 and -$3.32 in Q1 2025.